Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to $76.7 million.

  • Viking Therapeutics' Total Current Liabilities rose 17967.39% to $76.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $76.7 million, marking a year-over-year increase of 17967.39%. This contributed to the annual value of $76.7 million for FY2025, which is 17967.39% up from last year.
  • As of Q4 2025, Viking Therapeutics' Total Current Liabilities stood at $76.7 million, which was up 17967.39% from $26.1 million recorded in Q3 2025.
  • In the past 5 years, Viking Therapeutics' Total Current Liabilities registered a high of $76.7 million during Q4 2025, and its lowest value of $8.8 million during Q4 2021.
  • Its 5-year average for Total Current Liabilities is $21.7 million, with a median of $17.4 million in 2023.
  • The largest annual percentage gain for Viking Therapeutics' Total Current Liabilities in the last 5 years was 17967.39% (2025), contrasted with its biggest fall of 4027.89% (2025).
  • Viking Therapeutics' Total Current Liabilities (Quarter) stood at $8.8 million in 2021, then skyrocketed by 150.02% to $21.9 million in 2022, then fell by 12.81% to $19.1 million in 2023, then soared by 43.26% to $27.4 million in 2024, then soared by 179.67% to $76.7 million in 2025.
  • Its last three reported values are $76.7 million in Q4 2025, $26.1 million for Q3 2025, and $32.0 million during Q2 2025.